SU548275A1 - The method of obtaining hyperimmune anti-purulent antitoxic human plasma - Google Patents
The method of obtaining hyperimmune anti-purulent antitoxic human plasmaInfo
- Publication number
- SU548275A1 SU548275A1 SU2339302A SU2339302A SU548275A1 SU 548275 A1 SU548275 A1 SU 548275A1 SU 2339302 A SU2339302 A SU 2339302A SU 2339302 A SU2339302 A SU 2339302A SU 548275 A1 SU548275 A1 SU 548275A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- human plasma
- antitoxic
- purulent
- hyperimmune anti
- obtaining
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Description
(54) СПОСОБ ПОЛУЧЕНИЯ ГИПЕРИММУННОЙ АНТИСИНЕГНОЙНОЙ АНТИТОКСИЧЕСКОЙ ЧЕЛОВЕЧЕСКОЙ(54) METHOD FOR OBTAINING A HYPERIMMUNIC ANTISINEGIC ANTITOXIC HUMAN
ПЛАЗМЫPLASMA
Препарат обла/чает высокой лечебной эффективностью при различных заболевани х, вызванных синегнойной палочкой (послеоперационный сепсис, пиелонефрит, посттравматический остеомиелит, ожоговый сепсис, осложнени открытых переломов).The drug has a high curative efficacy in various diseases caused by the pyocyanic stick (postoperative sepsis, pyelonephritis, post-traumatic osteomyelitis, burn sepsis, complications of open fractures).
Гипериммунную антисинегнойную антитоксическую человеческую плазму ввод т больным внутривенно из расчета 3-5 мл на 1 кг веса ежедневно или через день 3-6 раз в зависимости от т жести клинического течени патологического процесса.Hyperimmune antiseptic anti-toxic human plasma is administered intravenously to patients at the rate of 3-5 ml per 1 kg of body weight daily or every other day 3-6 times depending on the severity of the clinical course of the pathological process.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU2339302A SU548275A1 (en) | 1976-03-31 | 1976-03-31 | The method of obtaining hyperimmune anti-purulent antitoxic human plasma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU2339302A SU548275A1 (en) | 1976-03-31 | 1976-03-31 | The method of obtaining hyperimmune anti-purulent antitoxic human plasma |
Publications (1)
Publication Number | Publication Date |
---|---|
SU548275A1 true SU548275A1 (en) | 1977-02-28 |
Family
ID=20653954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU2339302A SU548275A1 (en) | 1976-03-31 | 1976-03-31 | The method of obtaining hyperimmune anti-purulent antitoxic human plasma |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU548275A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
-
1976
- 1976-03-31 SU SU2339302A patent/SU548275A1/en active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
RU96101193A (en) | ANTIBODY FRAGMENTS IN THERAPY | |
DE69418601T2 (en) | GUANID DERIVATIVES WITH THERAPEUTIC EFFECT | |
RU92016463A (en) | APPLICATION OF DERIVATIVES OF TISSTINES FOR THE MANUFACTURE OF MEDICINES WITH IMMUNOMODING EFFECT, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS | |
GB1499035A (en) | Antistaphylococcus human immune globulin and method of preparing same | |
SU548275A1 (en) | The method of obtaining hyperimmune anti-purulent antitoxic human plasma | |
RU93042874A (en) | POLYPEPTIDE NATURE COMPOUNDS, METHOD FOR THEIR PRODUCTION, A COMPOSITION ON THEIR BASIS, THEIR APPLICATION IN ANTI-CANCER THERAPY | |
ES2044848T3 (en) | USE OF PETASITE EXTRACTS TO PREPARE A MEDICATION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES. | |
Bloom et al. | Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: A double-blind cross-over study with methyldopa. | |
Merritt | Corticotropin and cortisone in diseases of the nervous system | |
KR960700711A (en) | Medicine for treating or preventing cerebrovascular diseases | |
SU1105202A1 (en) | Method of treatment of gastric ulcer and duodenal ulcer | |
IE853206L (en) | Use of aminosulfonic acids in treatment of inflammatory¹conditions | |
Mwetta et al. | Community treatment with ivermectin for onchocerciasis in the east Usambara mountains | |
SU1261665A1 (en) | Method of treatment of thymomegalia of children | |
SU1169655A1 (en) | Method of treatment of thrombolytic diseases of the artery of the extremities | |
RU2166960C2 (en) | Method for preventing early stage sepsis in children having severe burns | |
SU1337101A1 (en) | Method of treatment of erysipelatous inflammation | |
RU2120292C1 (en) | Method for treating cerebrovascular crisis | |
KR920021152A (en) | Anti-neurotoxic activity of the methyl ester of GM_VII ganglioside and its therapeutic use | |
Yatskov | Neurological characteristic of the diseases caused by venomous medusa Gonionemus vertens vertens). | |
Bell | 3. The Treatment of Amoebic Dysentery | |
RU2003344C1 (en) | Method for burn disease treatment | |
SU1136798A1 (en) | Method of treatment of hyperactive behavour | |
RU93044773A (en) | METHOD FOR TREATING DISORDERS OF THE MENSTRUAL CYCLE |